Search Results

Crossbow Therapeutics, Inc. today announced the nomination of its first development candidate, CBX-250, a first-in-class, potent, and specific T-cell engager (TCE) for the treatment of myeloid leukemia.

Crossbow Therapeutics, Inc. today announced an $80 million Series A funding round led by MPM BioImpact and Pfizer Ventures, with participation from Polaris Partners, BVF Partners, Eli Lilly and Company, Mirae Asset Venture Investment, and Mirae Asset Capital.

hubXchange’s Antibody Therapeutics Xchange Boston 2026 brings together senior scientists and executives from leading pharma and biotech companies for a highly interactive, discussion-driven meeting focused on advancing next-generation antibody therapeutics. The event features expert presentations, roundtables, 1:1 meetings, and networking sessions covering target selection, lead optimization, multispecific engineering, and ADC innovation. Designed to foster collaboration and accelerate discovery, this one-day forum offers valuable insights from top industry leaders. Join us in Boston on April 28, 2026